Global Calcipotriene Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Calcipotriene Drugs Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Calcipotriene Drugs market finds that the global Calcipotriene Drugs market reached a value of USD 1000.64 million in 2022. It’s expected that the market will achieve USD 1335.83 million by 2028, exhibiting a CAGR of 4.93% during the forecast period.

Company Overview:

LEO Pharma Inc. is one of the major players operating in the Calcipotriene Drugs market, holding a share of 58.23% in 2023.

LEO Pharma A/S is a multinational Danish pharmaceutical company, founded in 1908, with a presence in about 100 countries. Its headquarters are in Ballerup, near Copenhagen.

Hexal AG develops, produces, and markets generic pharmaceuticals. The Company offers drugs and prescription and non-prescription medicines for asthma, high blood pressure, colds, cancer, osteoporosis, pain, parkinsons, and much more. Hexal markets its products worldwide.

Segmentation Overview:

Among different product types, Calcitrene (Enstilar,Kyntheum,Taclonex,Dovobet) segment is anticipated to contribute the largest market share in 2028.

Dovonex Dovonex (calcipotriene 0.005%) is a man-made, topical form of vitamin D that may be used to treat plaque psoriasis. It works by slowing down the overproduction of skin cells which eases inflamed, scaly areas. Dovonex is available as a cream or ointment. The topical scalp lotion has been discontinued.

Sorilux Sorilux is a prescription medication used to treat plaque psoriasis. Sorilux belongs to a group of drugs called synthetic vitamin D3 derivatives. The exact way Sorilux works to treat plaque psoriasis is unknown. This medication comes in the form of a foam. It is usually applied to the affected skin twice daily. Common side effects of Sorilux foam are irritation, redness, and itching of the skin treated.
Dovobet Dovobet is a fixed-dose combination of the steroid betamethasone dipropionate (Rinderon-DP) and the vitamin D3 calcipotriol (Dovonex).
Enstilar Enstilar® (calcipotriene and betamethasone dipropionate) Foam is a prescription medicine used on the skin (topical) to treat plaque psoriasis in people 12 years of age and older.
Taclonex Taclonex comes in two dosage forms. Taclonex Ointment is a prescription medicine that is for use on the skin only. The ointment is used to treat psoriasis vulgaris in adults 18 years of age and older. Taclonex Topical Suspension (liquid) is a used to treat plaque psoriasis of the scalp and body in people 12 years and older.

Key Companies in the global Calcipotriene Drugs market covered in Chapter 3:

HEXAL AG
Chongqing Huapont Pharmaceutical Co., Ltd.
Lupin
Others
Mayne Pharma
LEO Pharma Inc.
Bright Future Pharmaceutical

In Chapter 4 and Chapter 14.2, on the basis of types, the Calcipotriene Drugs market from 2018 to 2029 is primarily split into:

Dovonex
Sorilux
Dovobet
Enstilar
Taclonex

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Calcipotriene Drugs market from 2018 to 2029 covers:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)